logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Sophia Frentzas

monash health
H指数:19
被引数:2,388

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: 1-Year Follow-Up After Final Analysis of the ENGOT-en9/LEAP-001 Phase 3 Trial

一线仑伐替尼联合帕博利珠单抗与化疗治疗晚期子宫内膜癌：ENGOT-en9/LEAP-001 III期试验最终分析后的1年随访

International Journal of Gynecological Cancer
IF4.7
2025-11-110
PRE
Christian Marth; Richard G. Moore; Mariusz Bidziński; Vanda Salutari; Özden Altundağ; Maria Jesús Rubio; Tally Levy; Alison Stillie; Christof Vulsteke; Ralf Witteler; Kazuya Ariyoshi; Xiaohua Wu; Sophia Frentzas; André Mattar; Brian M. Slomovitz; Stephanie Lheureux; Xiaojun Chen; Kosei Hasegawa; Manuel Magallanes; Chel Hun Choi
PHASE 1 DOSE ESCALATION OF EO1001, AN ORAL BRAIN-PENETRATING PAN-ERBB INHIBITOR, IN ADVANCED CANCER: PRELIMINARY RESULTS FROM AN ONGOING PHASE 1-2A CLINICAL TRIAL

I期剂量递增研究：EO1001（一种口服的脑穿透性泛ERBB抑制剂）在晚期癌症中的应用，来自一项正在进行的I期-2A期临床试验的初步结果

NEURO-ONCOLOGY
IF13.4
2025-11-010
OAAI
Frentzas, Sophia; Ameratunga, Malaka; Body, Amy; Day, Daphne; Kelly, Richard; Macquire, Penelope; Malik, Yasmin; Murphy, Lauren; Neeman, Jeremy; Tan, Siang; Bacha, Jeffrey; Kanekal, Sarath; Li, Mike; Nisbet, Ian; Sankar, Neil; Skoff, Kathy; Brown, Dennis; Ahern, Elizabeth
First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations

yes相关蛋白 (YAP)/转录增强子激活结构域 (TEAD) 抑制剂VT3989在患有晚期实体瘤的患者 (pts) 中富集了恶性间皮瘤和其他具有神经纤维瘤病2 (NF2) 突变的肿瘤

CANCER RESEARCH
IF16.6
2023-04-1423
PRE
Yap, Timothy A.; Kwiatkowski, David J.; Desai, Jayesh; Dagogo-Jack, Ibiayi; Millward, Michael; Kindler, Hedy L.; Tolcher, Anthony W.; Frentzas, Sophia; Thurston, Archie W.; Post, Len; Dorr, F. Andrew
ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+metastatic breast cancer previously treated with T-DM1
CANCER RESEARCH
IF16.6
2023-03-011
PRE
Hurvitz, Sara; Kalinsky, Kevin; Ganju, Vinod; Ali, Kashif; Agrawal, Laila; Gradishar, William; Sledge, George; Thummala, Anu; Chan, Arlene; Frentzas, Sophia; Sohn, Joo Hyuk; Park, Kyong-Hwa; Park, Keon Uk; Shannon, Catherine; Drago, Joshua; Tolaney, Sara; Rugo, Hope; Press, Michael F.; Alika, Alex; Xu, Dong; Lu, Janice; Tripathy, Debu
A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens
CANCER RESEARCH
IF16.6
2022-02-150
PRE
Lu, Janice; Kalinsky, Kevin M.; Tripathy, Debu; Sledge, George W.; Gradishar, William; O'Regan, Ruth; O'Shaughnessy, Joyce; Modi, Shanu; Drago, Joshua; Park, Haeseong; McCartney, Amelia; Frentzas, Sophia; Shannon, Catherine; Cuff, Katharine; Eek, Richard; Martin, Miguel Idzwan; Curigliano, Giuseppe; Jerusalem, Guy; Huang, Chiun-Sheng; Press, Michael; Li, Matt; Xu, Dong; Song, Cynthia; Huhn, Richard; Yan, Jinchun; Hurvitz, Sara

研究方向

暂未获取到该数据
J
Jayesh Desai
H 指数:67论文数:651被引数:2.9万
A
Andrew R. Reynolds
H 指数:35论文数:128被引数:6,289
S
Shane Foo
H 指数:12论文数:63被引数:1,430
M
Michael Millward
H 指数:61论文数:456被引数:1.6万
T
Tarek Meniawy
H 指数:34论文数:177被引数:4,749
P
Peter Vermeulen
H 指数:45论文数:198被引数:6,922
B
Ben Tran
H 指数:38论文数:453被引数:6,500
V
Victoria L. Bridgeman
H 指数:14论文数:36被引数:1,804
甘慧 封面图
甘慧
H 指数:55论文数:594被引数:1.4万
D
David Cunningham
H 指数:153论文数:2,060被引数:13.0万